Skip to main content
. 2015 Sep 15;32(1):42–50. doi: 10.1016/j.joa.2015.08.001

Table 3a.

Clinical course of case A.

CCr (mL/min) Rivaroxaban (ng/mL) Anti-factor Xa activity (IU/mL) PT (s) APTT (s)
Rivaroxaban
 10 mg once daily (6.5 h after) 47.9 783.0 3.48 23.8 38.2



Apixaban
 2.5 mg twice daily (5.5 h after) 49.0 1.42 14.8 30.9